"The Company expects to report net revenue was approximately $1.1 million, an increase of approximately 150% from the previous quarter. Revenue growth in the second quarter was led by the Shapiro MD product line, sold through Immudyne’s majority owned subsidiary, Immudyne PR, LLC. Immudyne’s strategic additive business also increased approximately 74% from the previous quarter."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.